Precision cytokine modulation to overcome tumor microenvironment-driven resistance to immune checkpoint blockade [0.03%]
精准调控细胞因子以克服免疫检查点抑制剂治疗的肿瘤微环境耐药性问题
Xiaodong Wang,Junjie Wang,Qianqian Wang et al.
Xiaodong Wang et al.
Immune checkpoint inhibitors (ICIs) can elicit durable remissions, yet most solid tumors show primary non-response or acquired resistance because the tumor microenvironment (TME) limits T-cell priming, trafficking and effector fitness. Cyto...
Harnessing microRNAs in lung cancer: The future of diagnosis and precision therapy [0.03%]
微小核糖核酸在肺癌诊断和精准治疗中的应用前景
Daniela Alexandre,Pedro V Baptista,Carla Cruz
Daniela Alexandre
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related death, driven by late diagnosis and therapeutic resistance. microRNAs (miRs) regulate post-transcriptional networks across cancer hallmarks and are unusually sta...
Current landscape of PDT-based combination therapy for cutaneous squamous cell carcinoma: From molecular mechanisms to clinical practice [0.03%]
基于光动力疗法的皮肤鳞状细胞癌联合治疗现状：从分子机制到临床实践
Ziwei Kang,Guorong Yan,Guolong Zhang
Ziwei Kang
Photodynamic therapy (PDT) has been extensively applied in the management of superficial cutaneous squamous cell carcinoma (cSCC). However, the efficacy of PDT was limited by issues including poor tissue penetration and hypoxia. In recent y...
The interplay between cytokines and immune checkpoints in breast cancer therapy [0.03%]
细胞因子与免疫检查点在乳腺癌治疗中的相互作用
Ying Wu,Yin Zhu,Qing Cang et al.
Ying Wu et al.
Breast cancer (BC) immunotherapy has transformed treatment paradigms, yet response rates remain limited by the complex interplay between cytokine networks and immune checkpoints. This review synthesizes emerging evidence on how cytokines dy...
Emerging multi-omics biomarkers in glioblastoma: Integrative insights from genomics to metabolomics [0.03%]
胶质母细胞瘤中的新兴多组学生物标志物：从基因组学到代谢组学的综合见解
Ganesh S Kakde,Tikam Chand Dakal,Pawan Kumar Maurya
Ganesh S Kakde
Glioblastoma (GBM) is the most malignant form of primary brain tumor in adults, described by profound molecular heterogeneity, rapid progression, and limited therapeutic response. Despite advances in chemotherapy (TMZ), radiotherapy, and su...
Wenchao Bi,Xue Li,Huajun Zhao et al.
Wenchao Bi et al.
As the most abundant innate immune cells in bone marrow and peripheral blood, neutrophils were once considered functionally homogeneous and exerted inflammatory and anti-infection functions. However, emerging evidence reshapes the perceptio...
Histone acetyltransferase HBO1 in cancer biology: Essential mechanisms and implications for targeted therapeutics [0.03%]
组蛋白乙酰转移酶HBO1在癌症生物学中的作用机制及其在靶向治疗中的意义
Alissa D Marchione,Katie L Kathrein
Alissa D Marchione
The histone acetyltransferase complex HBO1 (KAT7) is an oncogenic regulator across multiple cancers, promoting cell proliferation and migration. Though clinically important, no targeted therapies address HBO1 dysregulation. HBO1 forms compl...
SCF-FBXO31 E3 ubiquitin ligase in cancer: Molecular insights and clinical implications [0.03%]
SCF-FBXO31 泛素连接酶在癌症中的作用：分子机制及临床意义
Osheen Sahay,Abhayananda Behera,Chandra Biswas et al.
Osheen Sahay et al.
F-box only protein 31 (FBXO31), a substrate adapter of SKP1-Cullin1-F-box (SCF) E3 ubiquitin ligase, was first identified as a candidate tumor suppressor in breast cancer due to its role in inducing senescence. Over the past two decades, FB...
Targeting glycolysis in prostate cancer: Molecular mechanisms and therapeutic advances [0.03%]
靶向前列腺癌糖酵解：分子机制和治疗进展
Jiexiang Zhang,Tongtong Zhang,Dexin Song et al.
Jiexiang Zhang et al.
Prostate cancer (PCa) is the second most common cancer among men worldwide and poses a significant threat to male health. A key feature of tumor progression is metabolic reprogramming, which involves the abnormal activation of glycolysis. T...
Protein palmitoylation and immune regulation in pancreatic ductal adenocarcinoma: Integrating insights from cross-cancer studies [0.03%]
胰腺导管腺癌中的蛋白质棕榈酰化与免疫调节：跨癌症研究的新见解
Xiaotong Cui,Changlei Li,Xue Zhong et al.
Xiaotong Cui et al.
Pancreatic ductal adenocarcinoma (PDAC) is characterized by an immunologically "cold" tumor microenvironment (TME), marked by a dense stromal barrier, impaired antigen presentation, and extensive infiltration of immunosuppressive cells. In ...